EGFR Mutation Positive Stage IV Non-Small-Cell Lung Cancer: Treatment Beyond Progression - Wikidata - wikimedia - TriplyDB

EGFR Mutation Positive Stage IV Non-Small-Cell Lung Cancer: Treatment Beyond Progression

EGFR Mutation Positive Stage IV Non-Small-Cell Lung Cancer: Treatment Beyond Progression

http://www.wikidata.org/entity/Q34650994

about

Effects of erlotinib therapy on [(11)C]erlotinib uptake in EGFR mutated, advanced NSCLC.Intercalated chemotherapy and erlotinib for non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations.Management of NSCLC Disease Progression After First-Line EGFR Tyrosine Kinase Inhibitors: What Are the Issues and Potential Therapies?

P2860

Q36558808-041249E9-064E-46F6-9E9F-F038E1B28612 Q37357699-B468A804-F1B8-40D0-B29B-4C6169E1FA96 Q38821038-2005BB9A-9908-41FB-9E2A-0FE26CCA419F

P2860

EGFR Mutation Positive Stage IV Non-Small-Cell Lung Cancer: Treatment Beyond Progression

http://www.wikidata.org/entity/Q34650994

description

2014 nî lūn-bûn

@nan

2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

EGFR Mutation Positive Stage IV Non-Small-Cell Lung Cancer: Treatment Beyond Progression

@ast

EGFR Mutation Positive Stage IV Non-Small-Cell Lung Cancer: Treatment Beyond Progression

@en

EGFR Mutation Positive Stage IV Non-Small-Cell Lung Cancer: Treatment Beyond Progression

@nl

type

label

EGFR Mutation Positive Stage IV Non-Small-Cell Lung Cancer: Treatment Beyond Progression

@ast

EGFR Mutation Positive Stage IV Non-Small-Cell Lung Cancer: Treatment Beyond Progression

@en

EGFR Mutation Positive Stage IV Non-Small-Cell Lung Cancer: Treatment Beyond Progression

@nl

prefLabel

EGFR Mutation Positive Stage IV Non-Small-Cell Lung Cancer: Treatment Beyond Progression

@ast

EGFR Mutation Positive Stage IV Non-Small-Cell Lung Cancer: Treatment Beyond Progression

@en

EGFR Mutation Positive Stage IV Non-Small-Cell Lung Cancer: Treatment Beyond Progression

@nl

P1433

Q34650994-1068032E-7744-480D-8355-9728BC87DFC8

P1476

Q34650994-29ACD63B-2AE7-4E82-A5F9-6A21BB14815D

P2093

Q34650994-7F69E3F9-6207-4496-8D01-08463C61B1B1

Q34650994-8A05EF64-1E93-43B1-9B45-F56B3FC15CE2

Q34650994-BAE5B4D4-CE50-4AC4-BF68-6953AAEB7DD0

Q34650994-C073F070-3F75-4769-902E-288D2FCB61E4

Q34650994-EE44E829-20A2-4C6E-8E3C-E834541A362E

P2860

Q34650994-036CC9B2-0E85-455F-8208-D5641AF0D478

Q34650994-092EA466-8F33-430A-9EF2-06575DE28E2D

Q34650994-0AA595F2-853B-40D5-BF20-1FE63E91E43B

Q34650994-27C6DC26-8ADE-4618-A34A-4D16491959CC

Q34650994-2B650EEB-881E-480A-B823-1D18FC44B3F0

Q34650994-2DD70821-4877-4A96-B943-C44BBE189BE0

Q34650994-3E63B7B6-AC0A-4A81-8E1D-D192BE91F4E1

Q34650994-3E806894-81F1-4F56-A32E-C26CABB45364

Q34650994-3EB4B1E9-6BB8-4396-848C-CEDDFF044F34

Q34650994-3F133678-B54F-410F-8B38-00124ED0347D

P304

Q34650994-A35AB7CA-E4F9-4EB9-83B2-4E46972D8B6A

P31

Q34650994-FD2E6D1A-8658-49A1-A370-161AB1E082AC

P356

Q34650994-4A3A8781-C2DF-4163-A536-2430BB6FAFEC

P478

Q34650994-0D1750E5-6A1C-4A94-B81E-179E2E0C1E24

P577

Q34650994-372BD5EA-7580-4F88-83C5-D8EDF51DFA4F

P5875

Q34650994-2601DFAB-E469-4BA6-8FA5-3D4E0FCD4E2C

P698

Q34650994-F7B39C38-6E80-4B6E-A38F-8C03535839CE

P932

Q34650994-3A040E26-9497-48B3-9835-ED0FA638DA58

P356

FONC.2014.00350

P1433

Frontiers in Oncology

P1476

EGFR Mutation Positive Stage IV Non-Small-Cell Lung Cancer: Treatment Beyond Progression

@en

P2093

Katrien Vandecasteele

http://www.w3.org/2001/XMLSchema#string

Katrijn Van Assche

http://www.w3.org/2001/XMLSchema#string

Liesbeth Ferdinande

http://www.w3.org/2001/XMLSchema#string

Veerle Surmont

http://www.w3.org/2001/XMLSchema#string

Yolande Lievens

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

P304

350

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FONC.2014.00350

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2014-12-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

270054728

http://www.w3.org/2001/XMLSchema#string

P698

25538894

http://www.w3.org/2001/XMLSchema#string

P932

4259002

http://www.w3.org/2001/XMLSchema#string